• Leone Nauri
Part of the Updates in Surgery book series (UPDATESSURG)


Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of unknown etiology that predominantly affects young adults. It can involve any part of the gastrointestinal tract, most commonly, the terminal ileum, the colon, or both, and its course is characterized by exacerbations and remissions. It may also involve organs outside the gastrointestinal tract. Some of these extraintestinal manifestions are true components of CD while others are complications caused by malnutrition, chronic inflammation, or the side effects of therapy, which make the differential diagnosis accordingly difficult [1,2]. Moreover, the extraintestinal manifestations may or may not correlate with disease activity but nonetheless can have a high impact on the quality of life, morbidity, and mortality of CD patients.


Inflammatory Bowel Disease Primary Sclerosing Cholangitis Autoimmune Hepatitis Liver Abscess Extraintestinal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Solis Herruzo JA, Solis-Munoz P (2007) Hepatobiliary manifestations of inflammatory bowel disease. Rev Esp Enferm Dig 99:525–542PubMedGoogle Scholar
  2. 2.
    Weismuller TJ, Wedemeyer J, Kubicka S et al (2008) The challenges in primarysclerosing cholangitis — Aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48:38–57CrossRefGoogle Scholar
  3. 3.
    Thomas CH (1873) Ulceration of the colon with a much enlarged fatty liver. Trans Pathol Soc Phil 4:87–88Google Scholar
  4. 4.
    Lister JD (1899) A specimen of diffuse ulcerative colitis with secondary diffuse hepatitis. Trans Pathol Soc Lon 50:130–134Google Scholar
  5. 5.
    Perrett AD, Higgins G, Johnston HH et al (1971) The liver in Crohn’s disease. Q J Med 40:187–209PubMedGoogle Scholar
  6. 6.
    Atkinson AJ, Carrol WW (1964) Sclerosing cholangitis association with regional enteritis. JAMA 188:183–184PubMedGoogle Scholar
  7. 7.
    Rasmussen HH, Fallingborg JF, Mortensen PB et al (1997) Hepatobiliary dysfunction and PSC in patients with Crohn’s disease. Scan J Gastroenterol 32:604–610CrossRefGoogle Scholar
  8. 8.
    Okada H, Mizuno M, Yamamoto K, Tsuji T (1966) Primary sclerosing cholangitis in Japanese patients: association with IBD. Acta Med Okayama 50:227–235Google Scholar
  9. 9.
    Chapman RW, Angus PW (1999) The effect of gastrointestinal disease on the liver and biliary tract. In: Oxford textbook of clinical hepatology. Oxford medical publications. Oxford University Press, Oxford New York Tokyo, pp 1686–1691Google Scholar
  10. 10.
    Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzime results in asymptomatic patients. N Engl J Med 342:1266–1271CrossRefPubMedGoogle Scholar
  11. 11.
    Delbert (1924) Bull Mem Soc Chir Paris 50:1144–1146Google Scholar
  12. 12.
    Angulo P, Maor-Kendler Y, Lindor KD (2002) Small-duct PSC: a long-term follow-up study. Hepatology 35:1494–1500CrossRefPubMedGoogle Scholar
  13. 13.
    Escorell A, Pares A, Rodes J et al (1994) Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol 21:789–791Google Scholar
  14. 14.
    Okolicsanyi L, Fabris L, Viaggi S et al (1996) Primary sclerosing cholangitis: clinical presentation, Natural history of prognostic variables: an italian multicenter study. Eur J Gastroenterol Hepatol 8:685–691PubMedGoogle Scholar
  15. 15.
    Tanaka A, Takamori Y, Toda G et al (2008) Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int 28(7):983–998PubMedGoogle Scholar
  16. 16.
    Broome U, Olsson R, Loof L et al (1966) Natural history and prognostic factors in 305 Swedish patients with PSC. Gut 38:610–615CrossRefGoogle Scholar
  17. 17.
    Chapman RW, Arborgh BA, Rhodes JM et al (1980) PSC: review of its clinical features, cholangiography, and hepatic histology. Gut 21:870–877CrossRefPubMedGoogle Scholar
  18. 18.
    MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J (1983) PSC: findings on cholangiography and pancreatography, Radiology 149:39–44PubMedGoogle Scholar
  19. 19.
    Ludwig J, Viggiano RT, McGill DB (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed. Mayo Clinic Proc 55:342–348Google Scholar
  20. 20.
    Margalit M, Elinav H, Han Y, Shalit M (2004) Liver abscess in IBD. J Gastr Hepatol 19:1338–1342CrossRefGoogle Scholar
  21. 21.
    Fraquelli M, Losco A, Visentin S et al (2001) Gallstone disease and related risk factors in patients with CD. Arch Intern Med 161:2201–2204CrossRefPubMedGoogle Scholar
  22. 22.
    Dowling RH, Bell DG, White J (1972) Lithogenic bile in patients with ileal dysfunction. Gut 13:415–420CrossRefPubMedGoogle Scholar
  23. 23.
    Millonig G, Kern M, Ludwiczek O et al (2006) subfulminant hepatitis B after infliximab in CD; need for HBV screening? World J Gastroenterol 12:974–976PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2010

Authors and Affiliations

  • Leone Nauri
    • 1
  1. 1.Hepatology Unit, Department of MedicineSan Camillo-Forlanini HospitalRomeItaly

Personalised recommendations